An analysis of the centrality metrics of this network identified a series of drug targets that can be classified as predicted new pharmacological targets for the treatment of glaucoma, since no entries on PubMed or clinicaltrials.gov were found: NUAK1 (NUAK family kinase 1), MAOB (monoamine oxidase B), HTRA1 (HtrA serine peptidase 1), LDHA (lactate dehydrogenase A), TNFRSF1A (the TNF receptor superfamily member 1A), FZD1 (frizzled class receptor 1), and MTNR1A (the metabotropic melatonin 1A receptor). Here, HTRA1 is linked to glaucoma.